针对麻疹病毒F蛋白的最小融合抑制剂的鉴定及构效关系分析。

IF 3.597 Q2 Pharmacology, Toxicology and Pharmaceutics
MedChemComm Pub Date : 2026-05-13 DOI:10.1039/D6MD00211K
Kazuya Kobayashi, Yuki Yamaguchi, Mizuki Itahara, Kazushige Hirata, Keisuke Aoki, Naoya Iwamoto, Hironori Hayashi, Eiichi Kodama and Shinya Oishi
{"title":"针对麻疹病毒F蛋白的最小融合抑制剂的鉴定及构效关系分析。","authors":"Kazuya Kobayashi, Yuki Yamaguchi, Mizuki Itahara, Kazushige Hirata, Keisuke Aoki, Naoya Iwamoto, Hironori Hayashi, Eiichi Kodama and Shinya Oishi","doi":"10.1039/D6MD00211K","DOIUrl":null,"url":null,"abstract":"<p >Although measles has been effectively controlled by vaccination, sporadic outbreaks still occur worldwide, highlighting the need for antiviral agents as complementary measures to achieve sustained elimination. Previously, we reported an anti-measles virus (MV) peptide derived from the HR2 region of MV fusion (F) protein that inhibits viral membrane fusion by disrupting the interaction between HR1 and HR2 regions. Here, we aimed to optimize this peptide by minimizing its sequence and interaction characteristics, thereby identifying a short derivative that retains potent antiviral activity. Structure–activity relationship analyses revealed that both hydrophobic and polar residues in HR2-derived peptides are crucial for efficient interaction with HR1. Thermal stability analysis of potential six-helical bundles using HR1-40, a 40-residue peptide of the HR1 region, showed no clear correlation with antiviral activity. To address this, we designed HR1Y, a C-terminally extended HR1 variant, which allowed a more accurate assessment of complex stability. Furthermore, molecular modeling of the HR2-derived peptide–HR1Y complex reproduced several experimental trends and provided structural insight into the HR1–HR2 interface. These findings clarify the structural determinants of fusion inhibitors against MV and support the rational optimization of HR2-derived antiviral peptides.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 6","pages":" 3100-3114"},"PeriodicalIF":3.5970,"publicationDate":"2026-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13227976/pdf/","citationCount":"0","resultStr":"{\"title\":\"Identification and structure–activity relationship analysis of minimal fusion inhibitors targeting measles virus F protein\",\"authors\":\"Kazuya Kobayashi, Yuki Yamaguchi, Mizuki Itahara, Kazushige Hirata, Keisuke Aoki, Naoya Iwamoto, Hironori Hayashi, Eiichi Kodama and Shinya Oishi\",\"doi\":\"10.1039/D6MD00211K\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Although measles has been effectively controlled by vaccination, sporadic outbreaks still occur worldwide, highlighting the need for antiviral agents as complementary measures to achieve sustained elimination. Previously, we reported an anti-measles virus (MV) peptide derived from the HR2 region of MV fusion (F) protein that inhibits viral membrane fusion by disrupting the interaction between HR1 and HR2 regions. Here, we aimed to optimize this peptide by minimizing its sequence and interaction characteristics, thereby identifying a short derivative that retains potent antiviral activity. Structure–activity relationship analyses revealed that both hydrophobic and polar residues in HR2-derived peptides are crucial for efficient interaction with HR1. Thermal stability analysis of potential six-helical bundles using HR1-40, a 40-residue peptide of the HR1 region, showed no clear correlation with antiviral activity. To address this, we designed HR1Y, a C-terminally extended HR1 variant, which allowed a more accurate assessment of complex stability. Furthermore, molecular modeling of the HR2-derived peptide–HR1Y complex reproduced several experimental trends and provided structural insight into the HR1–HR2 interface. These findings clarify the structural determinants of fusion inhibitors against MV and support the rational optimization of HR2-derived antiviral peptides.</p>\",\"PeriodicalId\":88,\"journal\":{\"name\":\"MedChemComm\",\"volume\":\" 6\",\"pages\":\" 3100-3114\"},\"PeriodicalIF\":3.5970,\"publicationDate\":\"2026-05-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13227976/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MedChemComm\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://pubs.rsc.org/en/content/articlelanding/2026/md/d6md00211k\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2026/md/d6md00211k","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

虽然麻疹已通过疫苗接种得到有效控制,但在世界范围内仍发生零星暴发,这突出表明需要抗病毒药物作为实现持续消除的补充措施。此前,我们报道了一种从MV融合(F)蛋白的HR2区域衍生的抗麻疹病毒(MV)肽,该肽通过破坏HR1和HR2区域之间的相互作用来抑制病毒膜融合。在这里,我们的目标是通过最小化其序列和相互作用特征来优化该肽,从而确定一个保留有效抗病毒活性的短衍生物。结构-活性关系分析表明,hr2衍生肽中的疏水残基和极性残基对于HR1的有效相互作用至关重要。利用HR1区40残基肽HR1-40对潜在的六螺旋束进行热稳定性分析,结果显示与抗病毒活性没有明显的相关性。为了解决这个问题,我们设计了HR1Y,这是一种c端扩展的HR1变体,可以更准确地评估复合物的稳定性。此外,hr2衍生肽- hr1y复合物的分子模型再现了几个实验趋势,并提供了HR1-HR2界面的结构洞察。这些发现阐明了抗MV融合抑制剂的结构决定因素,并支持hr2衍生抗病毒肽的合理优化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Identification and structure–activity relationship analysis of minimal fusion inhibitors targeting measles virus F protein

Identification and structure–activity relationship analysis of minimal fusion inhibitors targeting measles virus F protein

Although measles has been effectively controlled by vaccination, sporadic outbreaks still occur worldwide, highlighting the need for antiviral agents as complementary measures to achieve sustained elimination. Previously, we reported an anti-measles virus (MV) peptide derived from the HR2 region of MV fusion (F) protein that inhibits viral membrane fusion by disrupting the interaction between HR1 and HR2 regions. Here, we aimed to optimize this peptide by minimizing its sequence and interaction characteristics, thereby identifying a short derivative that retains potent antiviral activity. Structure–activity relationship analyses revealed that both hydrophobic and polar residues in HR2-derived peptides are crucial for efficient interaction with HR1. Thermal stability analysis of potential six-helical bundles using HR1-40, a 40-residue peptide of the HR1 region, showed no clear correlation with antiviral activity. To address this, we designed HR1Y, a C-terminally extended HR1 variant, which allowed a more accurate assessment of complex stability. Furthermore, molecular modeling of the HR2-derived peptide–HR1Y complex reproduced several experimental trends and provided structural insight into the HR1–HR2 interface. These findings clarify the structural determinants of fusion inhibitors against MV and support the rational optimization of HR2-derived antiviral peptides.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
MedChemComm
MedChemComm BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
CiteScore
4.70
自引率
0.00%
发文量
0
审稿时长
2.2 months
期刊介绍: Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry. In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书